Royalty Report: Medical, Diagnostic, Device – Collection: 391427

License Grant

The Australian Licensor, the Parent of the Licensee, hereby grants to Licensee a non-transferable, non-assignable, non-sublicensable, royalty-bearing and fee-bearing, limited license during the Term, in accordance with the terms and conditions of this Agreement under (1) the Licensed Rights and (2) Licensor’s ownership and legally enforceable rights in Biosensor, solely
a. to act as the regulatory authorisation holder for the purpose of, prosecuting the application of, and obtaining any, Regulatory Approval, including, being authorized to carry out any one or more Investigation for the purpose of (a) seeking approval from the relevant Regulatory Authorities to prosecute any approval for an Investigational Device to be used by an End User; and (b) applying for an IDE, including, obtaining approval for the Investigational Device to be shipped lawfully for the purpose of conducting Investigations for that Investigational Device, with an objective to submit such Investigations to the Regulatory Authority for Regulatory Approval.
The License is granted as an exclusive license in the Territory.

License Property

Technology related to measuring, or otherwise determining, the following (a) the amount or concentration of glucose; (b) the existence of biological markers of cancer; and (c) allergy/ immunology and hormones, each in a bodily fluid (e.g., saliva, blood) (each an “Indicator” and collectively the “Indicators”).

The Licensed Product comprises a product using the Organic Thin Film Technology, the Biosensor Technology encompassing but not limited to
a biosensor strip for one or more Indicator, including glucose Indicators; and

a proprietary smartphone application for the purpose reading, storing, analyzing and providing patient support programs for any one or more of the Indicators; and/or

a dedicated sensor strip reading device that is derived from the Licensed Rights.

Licensed Rights
1. The invention(s) described in PCT/AU2013/000207 and associated patent applications Australian provisional patent application 2012900885; PCT/AU2013/000207; Chinese patent application 201380022888.2; US patent application 14/382927;

2. The invention(s) described in the publication ‘printable organic thin film transistors for glucose detection incorporating ink jet printing of the enzyme recognition element, and the invention(s) described in PCT/AU2016/050555 and associated patent applications PCT/AU2016/050555 and the National Phase applications it will ultimately produce; and

3. all project intellectual property within the field,

Licensed Trademarks
Common law trade mark ‘Glucose Biosensor’

Field of Use

Licensee's flagship product is the Saliva Glucose Biosensor, a POCT expected to substitute the finger pricking invasive blood glucose monitoring for diabetic patients.

License Grant

Licensor of Australia grants to Licensee an exclusive license in the Territory, non-transferable, non-assignable, non- sublicensable, limited license during the Term, under the Licensed Rights and Licensor’s ownership and legally enforceable rights in Biosensor, solely
– to act as the regulatory authorisation holder for the purpose of, prosecuting the application of, and obtaining any, Regulatory Approval,
– to promote, market, import into the Territory, manufacture (either as the, or through an, Authorized Supplier), offer, sell, and supply Licensed Products in the Territory, solely for use in the Territory, and
– to provide reasonable customer support services to End Users of, and health care practitioners referring such End Users to use, the Licensed Products in the Territory on the use of the Licensed Products,

– to use the Licensed Products only for the purposes identified and permitted pursuant to the regulatory approval obtained in the Territory, and
– to collect for and on behalf of Licensor, Biosensor Data arising from use of Licensed Products in the Territory.

Licensor grants to Licensee a non-transferable, non-assignable, non-sublicensable, limited license during the Term to use the Licensed Trademarks, and to reproduce, and use (without any modification or editing not approved in advance in writing) any exact copies of any Licensed Material.

License Property

The Technology is related to measuring, or otherwise determining, the amount or concentration of glucose; the existence of biological markers of cancer; and allergy/ immunology and hormones, each in a bodily fluid such as saliva or blood.

The Biosensor Technology are products, including, meters, strips, and accessories, systems, methods, processes, applications, and implementation for or of measuring or otherwise determining the amount or concentration and existence of each Indicator in a bodily fluid. And, Proprietary Rights in and to Biosensor Technology.

The Licensed Product comprises a product using the Organic Thin Film Technology, the Biosensor Technology encompassing but not limited to
—  a biosensor strip for one or more Indicator, including glucose Indicators; and
—  a proprietary smartphone application for the purpose reading, storing, analyzing and providing patient support programs for any one or more of the Indicators; and/or
—  a dedicated sensor strip reading device
that is derived from the Licensed Rights.

Licensed property includes
—  The invention(s) described in PCT/AU2013/000207 and associated patent applications Australian provisional patent application 2012900885; PCT/AU2013/000207; Chinese patent application 201380022888.2; US patent application 14/382927;
—  The invention(s) described in the publication ‘printable organic thin film transistors for glucose detection incorporating ink jet printing of the enzyme recognition element, and the invention(s) described in PCT/AU2016/050555 and associated patent applications PCT/AU2016/050555 and the National Phase applications it will ultimately produce; and
—  all project intellectual property within the field,
—  and any other rights in relation to such inventions with respect to existing and future patents and rights with respect to existing and future patent applications and patentable inventions in respect of glucose detection.

The Common law trade mark is Glucose Biosensor.

Field of Use

The field of use is relating to measuring, or otherwise determining, the amount or concentration of glucose, and the existence of biological markers of cancer, allergy/immunology and hormones, in a bodily fluid.

End User includes any subject who provides a bodily fluid for the assessment of any one or more Indicator and performs such assessment using such provided bodily fluid and any individual who receives for the assessment of any one or more Indicator a bodily fluid of another and performs such assessment using such received bodily fluid.

License Grant

Licensor of Australia grants a non-transferable, non-assignable, non-sublicensable, limited license under the Licensed Rights and Licensor’s ownership and legally enforceable rights in Biosensor, solely
—  to act as the regulatory authorisation holder for the purpose of, prosecuting the application of, and obtaining any, Regulatory Approval, including, being authorized to carry out any one or more Investigation for the purpose of seeking approval from the relevant Regulatory Authorities to prosecute any approval for an Investigational Device to be used by an End User; and, applying for an IDE, including, obtaining approval for the Investigational Device to be shipped lawfully for the purpose of conducting Investigations for that Investigational Device, with an objective to submit such Investigations to the Regulatory Authority for Regulatory Approval.
—  to promote, market, import into the Territory, manufacture (either as the, or through an, Authorized Supplier), offer, sell, and supply Licensed Products in the Territory, solely for use in the Territory, and
—  to provide reasonable customer support services to End Users of, and health care practitioners referring such End Users to use, the Licensed Products in the Territory on the use of the Licensed Products,
—  to use the Licensed Products only for the purposes identified and permitted pursuant to the regulatory approval obtained in the Territory, and
—  to collect for and on behalf of Licensor, Biosensor Data arising from use of Licensed Products in the Territory.

The License is granted as an exclusive license in the Territory.

Licensor grants to Licensee a non-transferable, non-assignable, non-sublicensable, limited license during the Term to use the Licensed Trademarks, and to reproduce, and use (without any modification or editing not approved in advance in writing) any exact copies of any Licensed Material, solely in the Territory and solely for the purpose of reasonably promoting, marketing, offering, selling the Licensed Products, all in accordance with the terms and conditions of this Agreement.

License Property

The technology is related to measuring, or otherwise determining the amount or concentration of glucose; the existence of biological markers of cancer; and, allergy/ immunology and hormones, each in a bodily fluid.

The Licensed Product comprises a product using the Organic Thin Film Technology, the Biosensor Technology encompassing but not limited to
—  a biosensor strip for one or more Indicator, including glucose Indicators; and
—  a proprietary smartphone application for the purpose reading, storing, analyzing and providing patient support programs for any one or more of the Indicators; and/or
—  a dedicated sensor strip reading device

The trade mark is Glucose Biosensor.

Field of Use

The use is for or of measuring or otherwise determining the amount or concentration and existence of each Indicator in a bodily fluid.  Licensees objective is to introduce and launch the Saliva Glucose Biosensor, a diagnostic test that stems from the Biosensor Platform.
The “Licensed Products” are products consisting of a biosensor strip and smart device application or dedicated reader device that use the biosensor technology owned by the Licensor relating to measuring, or otherwise determining, the amount or concentration of glucose, and the existence of biological markers of cancer, allergy/immunology and hormones, in a bodily fluid.

License Grant

The Licensor of Australia, and Parent of the Licensee, granted an exclusive license to the Licensor’s proprietary rights to the biosensor technology used in the Licensed Products, worldwide and solely to
–  act as the authorized party for the purpose of prosecuting the application of, and obtaining any, regulatory approval for the Licensed Product, including being authorized to prosecute the approval for an investigational device required for the purpose of carrying out clinical studies;
–  manufacture, promote, market, import, offer, sell and distribute the Licensed Products;
–  provide reasonable customer support services on the use of the Licensed Products to end users of, and health care practitioners referring end users to, the Licensed Products;
–  use the Licensed Products only for the purposes identified and permitted pursuant to regulatory approval; and
–  collect data acquired from the Licensed Products.

License Property

The Licensed Products include (i) a biosensor strip for antibodies against SARS-CoV-2; (ii) a proprietary smartphone application for the purpose reading, storing, analyzing and providing patient support programs for any one or more of the Indicators for the purpose of measuring the amount or concentration of immunoglobulins (IgG, IgM, IgA) specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); and/or (iii) a dedicated sensor strip reading device for any one or more of the Indicators for the purpose of measuring the amount or concentration of immunoglobulins (IgG, IgM, IgA) specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

The trademark is COV-2 Biosensor.

Field of Use

Licensee is developing and commercializing a range of Biosensor based Point of Care (POCT) diagnostic tests that are developed in the modalities of clinical chemistry, immunology, tumor markers, allergens and endocrinology.  Licensee intends to introduce and launch COV2 diagnostic tests across the US, Europe, APAC and the rest of the world through appropriately qualified distributors.

License Grant

The Company assigned all of its patent rights on glucose monitoring technology to the Licensee. In exchange for the use of these patent rights the Company acquired a percentage of interest in Licensee and acquired the right to receive royalty payments on revenues generated by any product developed by Licensee that uses our glucose monitoring technology.  The transaction between the two companies is deemed to be an arm's-length transaction.

Field of Use

The glucose biosensor technology involves the measurement and monitoring of glucose levels in diabetes patients. The implanted Glucose Biosensor continuously monitors blood glucose without the need for finger sticks. SYBD's implanted biosensor can be programmed to monitor blood glucose according to a predetermined schedule, thus eliminating problems of patient compliance. The sensor alarms for dangerous, life threatening conditions such as hypoglycemia.

License Grant

Israel Licensor hereby irrevocably assigns and transfers to the Israel Licensee, under Incorporation, all rights in the Application for Patent Registration and the Sensor, patent application submitted in connection with a sensor for monitoring glucose concentration in the blood.

License Property

Licensor is the owner of rights in the application for the registration of a patent and/or any other right in connection with a sensor for calculating the glucose level in the blood.

Field of Use

The Licensee wishes to incorporate a company which shall receive the rights in the Application for Patent Registration and which shall act for the purpose of developing, marketing, selling and/or any other acts in connection with the Sensor.